Novo Nordisk (NYSE: NVO) announced the top-line results from the LEADER trial, which investigated the cardiovascular safety of Victoza® (liraglutide) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE